학술논문
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Document Type
Letter
Author
Source
Subject
*CHRONIC lymphocytic leukemia
*BRUTON tyrosine kinase
*CHRONIC leukemia
*MONONUCLEAR leukocytes
*
*
*
Language
ISSN
1042-8194
Abstract
The multiplex-PCR method was also applied to 5 DNA samples from healthy donors and additional 27 ibrutinib-naïve patients with CLL, without finding any mutation in BTK gene. The irreversible Bruton tyrosine kinase (BTK) inhibitor ibrutinib has changed the therapeutic landscape of patients affected by chronic lymphocytic leukemia (CLL), leading to high clinical response rates and durable remissions both in treatment-naïve or in the relapsed/refractory setting, also in patients with unmutated immunoglobulin genes or harboring I TP53 i deletion or mutations [[1], [3]]. The remaining CLL patients (60-70%) harbored BTK or PLC 2 mutations, which were clearly associated with a reduction in ibrutinib activity and predictive of CLL progression. [Extracted from the article]